KYTX (Kyverna Therapeutics) Current Deferred Revenue : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Kyverna Therapeutics's current deferred revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

Kyverna Therapeutics Current Deferred Revenue Historical Data

The historical data trend for Kyverna Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Current Deferred Revenue Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Current Deferred Revenue

6.00

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Current Deferred Revenue	Get a 7-Day Free Trial					-	-	-	-	-

Kyverna Therapeutics Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.